Throughout the last decade, the use of energy drinks has been increasingly looked upon with caution as potentially dangerous due to their perceived strong concentration of caffeine aside from other substances such as ...Throughout the last decade, the use of energy drinks has been increasingly looked upon with caution as potentially dangerous due to their perceived strong concentration of caffeine aside from other substances such as taurine, guarana, and L-carnitine that are largely unknown to the general public. In addition, a large number of energy drink intoxications have been reported all over the world including cases of seizures and arrhythmias. In this paper, we focus on the effect of energy drinks on the cardiovascular system and whether the current ongoing call for the products' sales and regulation of their contents should continue.展开更多
Chromatographic behavior of co-eluted compounds from un-extracted drug-free plasma samples was studied by LC-MS and LC-MS/MS with positive APCI.Under soft gradient,total ion chromatogram（TIC） consisted of two major ...Chromatographic behavior of co-eluted compounds from un-extracted drug-free plasma samples was studied by LC-MS and LC-MS/MS with positive APCI.Under soft gradient,total ion chromatogram（TIC） consisted of two major peaks separated by a constant lower intensity region.Early peak（0.15-0.4 min） belongs to polar plasma compounds and consisted of smaller mass ions（m/z〈 250）;late peak（3.6-4.6 min） belongs to thermally unstable phospholipids and consisted of fragments with mlz〈300.Late peak is more sensitive to variations in chromatographic and MS parameters.Screening of most targeted cardiovascular drugs at levels lower than 50 ng/mL has been possible by LC-MS for drugs with retention factors larger than three.Matrix effects and recovery,at 20 and 200 ng/mL,were evaluated for spiked plasma samples with 15 cardiovascular drugs,by MRM-LC-MS/MS.Average recoveries were above 90%and matrix effects expressed as percent matrix factor（%MF） were above 100%,indicating enhancement character for APCI.Large uncertainties were significant for drugs with smaller masses（m/z〈 250） and retention factors lower than two.展开更多
BACKGROUND Chronic heart failure(CHF)is a complex syndrome characterized by a progressive reduction of the left ventricular(LV)contractility,low exercise tolerance,and increased mortality and morbidity.Diastolic dysfu...BACKGROUND Chronic heart failure(CHF)is a complex syndrome characterized by a progressive reduction of the left ventricular(LV)contractility,low exercise tolerance,and increased mortality and morbidity.Diastolic dysfunction(DD)of the LV,is a keystone in the pathophysiology of CHF and plays a major role in the progression of most cardiac diseases.Also,it is well estimated that exercise training induces several beneficial effects on patients with CHF.AIM To evaluate the impact of a cardiac rehabilitation program on the DD and LV ejection fraction(EF)in patients with CHF.METHODS Thirty-two stable patients with CHF(age:56±10 years,EF:32%±8%,88%men)participated in an exercise rehabilitation program.They were randomly assigned to aerobic exercise(AER)or combined aerobic and strength training(COM),based on age and peak oxygen uptake,as stratified randomization criteria.Before and after the program,they underwent a symptom-limited maximal cardiopulmonary exercise testing(CPET)and serial echocardiography evaluation to evaluate peak oxygen uptake(VO2peak),peak workload(Wpeak),DD grade,right ventricular systolic pressure(RVSP),and EF.RESULTS The whole cohort improved VO2peak,and Wpeak,as well as DD grade(P<0.05).Overall,9 patients(28.1%)improved DD grade,while 23(71.9%)remained at the same DD grade;this was a significant difference,considering DD grade at baseline(P<0.05).In addition,the whole cohort improved RVSP and EF(P<0.05).Not any between-group differences were observed in the variables assessed(P>0.05).CONCLUSION Exercise rehabilitation improves indices of diastolic and systolic dysfunction.Exercise protocol was not observed to affect outcomes.These results need to be further investigated in larger samples.展开更多
目的应用序贯法探讨丙泊酚或不同剂量瑞马唑仑对舒芬太尼抑制老年患者气管插管反应的半数有效剂量(50%effective dose,ED_(50))的影响。方法选择2022年10至12月在气管插管全身麻醉下接受择期手术的老年患者,美国麻醉医师协会(American S...目的应用序贯法探讨丙泊酚或不同剂量瑞马唑仑对舒芬太尼抑制老年患者气管插管反应的半数有效剂量(50%effective dose,ED_(50))的影响。方法选择2022年10至12月在气管插管全身麻醉下接受择期手术的老年患者,美国麻醉医师协会(American Society of Anesthesiologists,ASA)分级Ⅰ、Ⅱ级,年龄65~80岁,将患者采用随机数字表法分为4组:丙泊酚组(P组,诱导时给予丙泊酚2mg/kg)和瑞马唑仑组(R1、R2、R3组,诱导时分别静脉注射瑞马唑仑0.2、0.3、0.4mg/kg)。麻醉诱导时给予Dixon序贯法设定剂量的舒芬太尼后,静脉注射丙泊酚或相应剂量瑞马唑仑及顺式阿曲库铵0.15mg/kg,待4个成串刺激(train of four,TOF)计数为0时行气管插管。若气管插管反应阳性,则下一例患者舒芬太尼剂量提高1个浓度梯度,否则降低1个浓度梯度,各相邻浓度之间的比为1∶1.1,直至出现7个转折点终止研究。采用Probit回归分析计算舒芬太尼抑制老年患者气管插管反应ED_(50)和95%有效剂量(95%effective dose,ED_(95))以及相应的95%置信区间(confidenceinterval,CI)。记录所有患者低血压、心动过缓、注射痛等不良反应的发生情况。结果本研究共纳入老年患者113例,P、R1、R2、R3组分别24、28、30、31例。丙泊酚2mg/kg或0.2、0.3、0.4mg/kg瑞马唑仑时舒芬太尼抑制老年患者气管插管反应的ED_(50)和ED_(95)及相应95%CI分别为:P组ED_(50)为0.236μg/kg(95%CI:0.218~0.256),ED_(95)为0.266μg/kg(95%CI:0.250~0.398);R1组ED_(50)为0.284μg/kg(95%CI:0.265~0.309),ED_(95)为0.329μg/kg(95%CI:0.306~0.478);R2组ED_(50)为0.239μg/kg(95%CI:0.221~0.260),ED_(95)为0.282μg/kg(95%CI:0.261~0.415);R3组ED_(50)为0.198μg/kg(95%CI:0.182~0.211),ED_(95)为0.231μg/kg(95%CI:0.216~0.303)。与P组相比,R1、R2、R3组低血压、心动过缓、注射痛发生率较低(P<0.05)。R2组舒芬太尼ED_(50)与P组相类似,但低血压、注射痛发生率与P组相比较低。结论随着瑞马唑仑剂量的增加,舒芬太尼抑制老年患者气管插管反应的ED_(50)逐渐降低;在ED_(50)相近的情况下,瑞马唑仑相较于丙泊酚诱导的低血压、心动过缓、注射痛发生率更低,因而在老年患者气管插管全身麻醉中,使用瑞马唑仑诱导更具有优势。展开更多
目的评价达格列净治疗2型糖尿病(T2DM)合并心血管疾病(CVD)的安全性、有效性及经济性,为临床治疗决策提供循证依据。方法检索PubMed、the Cochrane Library、Embase、Web of Science、中国知网、万方数据、维普网、中国生物医学文献数...目的评价达格列净治疗2型糖尿病(T2DM)合并心血管疾病(CVD)的安全性、有效性及经济性,为临床治疗决策提供循证依据。方法检索PubMed、the Cochrane Library、Embase、Web of Science、中国知网、万方数据、维普网、中国生物医学文献数据库以及国内外卫生技术评估(HTA)相关机构官方网站,收集达格列净治疗T2DM合并CVD的HTA报告、系统评价/Meta分析和药物经济学研究。资料提取、评价质量后,对纳入研究的结果进行描述性分析。结果共纳入文献13篇,其中系统评价/Meta分析10篇、药物经济学研究3篇。有效性方面,与安慰剂比较,达格列净可显著降低患者的糖化血红蛋白、体重、体重指数及血压水平,且未增加全因病死风险。安全性方面,达格列净未增加患者总体不良反应、主要心血管不良事件、心血管病死、心力衰竭住院、心肌梗死、脑卒中、骨折、肾功能减退的发生风险。经济性方面,英国及中国经济学研究认为,达格列净具有经济学优势;泰国经济学研究认为,该药不具有经济学优势。结论达格列净治疗T2DM合并CVD的有效性和安全性较好;经济性结论在不同国家存在差异,在我国当前医疗政策及药品价格背景下达格列净具有经济学优势。展开更多
目的探讨中西医结合治疗糖尿病心血管自主神经病变(DCAN)的临床疗效。方法选取2021年1月至2023年5月于石家庄市第二医院就诊的80例DCAN患者作为研究对象,采用随机数字表法分为对照组(40例)和观察组(40例),对照组采取常规西医治疗,观察...目的探讨中西医结合治疗糖尿病心血管自主神经病变(DCAN)的临床疗效。方法选取2021年1月至2023年5月于石家庄市第二医院就诊的80例DCAN患者作为研究对象,采用随机数字表法分为对照组(40例)和观察组(40例),对照组采取常规西医治疗,观察组在对照组基础上采用中医综合治疗(益气养阴活血汤+针灸),1个疗程为14 d,2个疗程宜间隔7 d,两组共治疗3个疗程。比较两组临床疗效;比较两组空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR);比较两组窦性RR间期标准差(SDNN)、全程NN节段的窦性RR间期标准差(SDANN)、全程相邻RR之差的均方根(RMSSD)、相邻RR间期差值>50 ms的个数占总窦性心搏个数的百分比(PNN50);比较两组不良反应发生率。结果观察组临床总有效率(90.00%)明显高于对照组(70.00%),差异有统计学意义(P<0.05)。两组治疗后FBG、2 h PBG、HbA1c、HOMA-IR均明显低于治疗前,且观察组均明显低于对照组,差异均有统计学意义(P<0.05)。两组治疗后SDNN、SDANN、RMSSD、PNN50均明显高于治疗前,且观察组均明显高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论中西医结合治疗DCAN临床疗效明显,能够有效改善血糖水平、心率变异性,且不增加不良反应,具有较高的临床参考价值。展开更多
目的探究达格列净联合常规治疗对2型糖尿病伴心力衰竭患者的心血管保护作用及对血清炎症因子和可溶性生长刺激表达基因2(sST2)水平的影响。方法前瞻性选取2020年9月至2022年8月江苏省昆山市第一人民医院收治的86例2型糖尿病伴心力衰竭...目的探究达格列净联合常规治疗对2型糖尿病伴心力衰竭患者的心血管保护作用及对血清炎症因子和可溶性生长刺激表达基因2(sST2)水平的影响。方法前瞻性选取2020年9月至2022年8月江苏省昆山市第一人民医院收治的86例2型糖尿病伴心力衰竭患者为研究对象,按随机数字表法分为对照组和观察组,各43例。对照组予以常规治疗降糖及抗心力衰竭治疗,观察组在对照组基础上增加达格列净治疗。比较两组治疗前、治疗6个月后的血糖[糖化血红蛋白(HbA1c)、空腹血糖、餐后2 h血糖(2 h PG)]、血脂[总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)]、心功能[左心室射血分数(LVEF)、血浆N端脑钠肽前体(NT-proBNP)、6 min步行试验(6MWT)]、血清指标[白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、sST2]水平及心血管事件及不良反应发生率。结果治疗6个月后,观察组的HbA1c、空腹血糖、2 h PG、总胆固醇、甘油三酯、LDL-C水平分别为(6.65±0.73)%、(6.25±1.54)mmol/L、(7.88±1.35)mmol/L、(3.87±0.85)mmol/L、(1.52±0.46)mmol/L、(2.41±0.63)mmol/L,均明显低于对照组[(7.07±0.85)%、(7.16±1.49)mmol/L、(8.82±1.48)mmol/L、(4.24±0.82)mmol/L、(1.73±0.51)mmol/L、(2.69±0.61)mmol/L],差异均有统计学意义(P<0.05)。治疗6个月后,观察组的LVEF、6MWT水平分别为(52.28±3.43)%、(424.87±72.58)m,均明显高于对照组[(50.79±3.25)%、(367.52±74.43)m],血浆NT-proBNP水平为(1778.65±224.37)pg/mL,低于对照组[(2943.41±256.22)pg/mL],差异均有统计学意义(P<0.05)。治疗6个月后,观察组的血清IL-1β、TNF-α、sST2水平分别为(6.60±1.14)pg/mL、(22.15±4.30)ng/L、(0.42±0.13)g/L,均明显低于对照组[(7.19±1.39)pg/mL、(29.68±5.24)ng/L、(0.50±0.16)g/L],差异均有统计学意义(P<0.05)。观察组心血管事件总发生率为9.30%,低于对照组(25.58%),差异有统计学意义(P<0.05)。两组均无严重不良反应发生。结论在使用常规降糖、抗心力衰竭治疗2型糖尿病伴心力衰竭患者基础上增加达格列净可有效降低其血糖、血脂及血清IL-1β、TNF-α、sST2水平,减少心血管事件的发生,具有一定心血管保护作用。展开更多
文摘Throughout the last decade, the use of energy drinks has been increasingly looked upon with caution as potentially dangerous due to their perceived strong concentration of caffeine aside from other substances such as taurine, guarana, and L-carnitine that are largely unknown to the general public. In addition, a large number of energy drink intoxications have been reported all over the world including cases of seizures and arrhythmias. In this paper, we focus on the effect of energy drinks on the cardiovascular system and whether the current ongoing call for the products' sales and regulation of their contents should continue.
基金supported by Dean of Scientific Research at Jordan University of Science and Technology(JUST)(No.159/ 2012)
文摘Chromatographic behavior of co-eluted compounds from un-extracted drug-free plasma samples was studied by LC-MS and LC-MS/MS with positive APCI.Under soft gradient,total ion chromatogram（TIC） consisted of two major peaks separated by a constant lower intensity region.Early peak（0.15-0.4 min） belongs to polar plasma compounds and consisted of smaller mass ions（m/z〈 250）;late peak（3.6-4.6 min） belongs to thermally unstable phospholipids and consisted of fragments with mlz〈300.Late peak is more sensitive to variations in chromatographic and MS parameters.Screening of most targeted cardiovascular drugs at levels lower than 50 ng/mL has been possible by LC-MS for drugs with retention factors larger than three.Matrix effects and recovery,at 20 and 200 ng/mL,were evaluated for spiked plasma samples with 15 cardiovascular drugs,by MRM-LC-MS/MS.Average recoveries were above 90%and matrix effects expressed as percent matrix factor（%MF） were above 100%,indicating enhancement character for APCI.Large uncertainties were significant for drugs with smaller masses（m/z〈 250） and retention factors lower than two.
文摘BACKGROUND Chronic heart failure(CHF)is a complex syndrome characterized by a progressive reduction of the left ventricular(LV)contractility,low exercise tolerance,and increased mortality and morbidity.Diastolic dysfunction(DD)of the LV,is a keystone in the pathophysiology of CHF and plays a major role in the progression of most cardiac diseases.Also,it is well estimated that exercise training induces several beneficial effects on patients with CHF.AIM To evaluate the impact of a cardiac rehabilitation program on the DD and LV ejection fraction(EF)in patients with CHF.METHODS Thirty-two stable patients with CHF(age:56±10 years,EF:32%±8%,88%men)participated in an exercise rehabilitation program.They were randomly assigned to aerobic exercise(AER)or combined aerobic and strength training(COM),based on age and peak oxygen uptake,as stratified randomization criteria.Before and after the program,they underwent a symptom-limited maximal cardiopulmonary exercise testing(CPET)and serial echocardiography evaluation to evaluate peak oxygen uptake(VO2peak),peak workload(Wpeak),DD grade,right ventricular systolic pressure(RVSP),and EF.RESULTS The whole cohort improved VO2peak,and Wpeak,as well as DD grade(P<0.05).Overall,9 patients(28.1%)improved DD grade,while 23(71.9%)remained at the same DD grade;this was a significant difference,considering DD grade at baseline(P<0.05).In addition,the whole cohort improved RVSP and EF(P<0.05).Not any between-group differences were observed in the variables assessed(P>0.05).CONCLUSION Exercise rehabilitation improves indices of diastolic and systolic dysfunction.Exercise protocol was not observed to affect outcomes.These results need to be further investigated in larger samples.
文摘目的应用序贯法探讨丙泊酚或不同剂量瑞马唑仑对舒芬太尼抑制老年患者气管插管反应的半数有效剂量(50%effective dose,ED_(50))的影响。方法选择2022年10至12月在气管插管全身麻醉下接受择期手术的老年患者,美国麻醉医师协会(American Society of Anesthesiologists,ASA)分级Ⅰ、Ⅱ级,年龄65~80岁,将患者采用随机数字表法分为4组:丙泊酚组(P组,诱导时给予丙泊酚2mg/kg)和瑞马唑仑组(R1、R2、R3组,诱导时分别静脉注射瑞马唑仑0.2、0.3、0.4mg/kg)。麻醉诱导时给予Dixon序贯法设定剂量的舒芬太尼后,静脉注射丙泊酚或相应剂量瑞马唑仑及顺式阿曲库铵0.15mg/kg,待4个成串刺激(train of four,TOF)计数为0时行气管插管。若气管插管反应阳性,则下一例患者舒芬太尼剂量提高1个浓度梯度,否则降低1个浓度梯度,各相邻浓度之间的比为1∶1.1,直至出现7个转折点终止研究。采用Probit回归分析计算舒芬太尼抑制老年患者气管插管反应ED_(50)和95%有效剂量(95%effective dose,ED_(95))以及相应的95%置信区间(confidenceinterval,CI)。记录所有患者低血压、心动过缓、注射痛等不良反应的发生情况。结果本研究共纳入老年患者113例,P、R1、R2、R3组分别24、28、30、31例。丙泊酚2mg/kg或0.2、0.3、0.4mg/kg瑞马唑仑时舒芬太尼抑制老年患者气管插管反应的ED_(50)和ED_(95)及相应95%CI分别为:P组ED_(50)为0.236μg/kg(95%CI:0.218~0.256),ED_(95)为0.266μg/kg(95%CI:0.250~0.398);R1组ED_(50)为0.284μg/kg(95%CI:0.265~0.309),ED_(95)为0.329μg/kg(95%CI:0.306~0.478);R2组ED_(50)为0.239μg/kg(95%CI:0.221~0.260),ED_(95)为0.282μg/kg(95%CI:0.261~0.415);R3组ED_(50)为0.198μg/kg(95%CI:0.182~0.211),ED_(95)为0.231μg/kg(95%CI:0.216~0.303)。与P组相比,R1、R2、R3组低血压、心动过缓、注射痛发生率较低(P<0.05)。R2组舒芬太尼ED_(50)与P组相类似,但低血压、注射痛发生率与P组相比较低。结论随着瑞马唑仑剂量的增加,舒芬太尼抑制老年患者气管插管反应的ED_(50)逐渐降低;在ED_(50)相近的情况下,瑞马唑仑相较于丙泊酚诱导的低血压、心动过缓、注射痛发生率更低,因而在老年患者气管插管全身麻醉中,使用瑞马唑仑诱导更具有优势。
文摘目的评价达格列净治疗2型糖尿病(T2DM)合并心血管疾病(CVD)的安全性、有效性及经济性,为临床治疗决策提供循证依据。方法检索PubMed、the Cochrane Library、Embase、Web of Science、中国知网、万方数据、维普网、中国生物医学文献数据库以及国内外卫生技术评估(HTA)相关机构官方网站,收集达格列净治疗T2DM合并CVD的HTA报告、系统评价/Meta分析和药物经济学研究。资料提取、评价质量后,对纳入研究的结果进行描述性分析。结果共纳入文献13篇,其中系统评价/Meta分析10篇、药物经济学研究3篇。有效性方面,与安慰剂比较,达格列净可显著降低患者的糖化血红蛋白、体重、体重指数及血压水平,且未增加全因病死风险。安全性方面,达格列净未增加患者总体不良反应、主要心血管不良事件、心血管病死、心力衰竭住院、心肌梗死、脑卒中、骨折、肾功能减退的发生风险。经济性方面,英国及中国经济学研究认为,达格列净具有经济学优势;泰国经济学研究认为,该药不具有经济学优势。结论达格列净治疗T2DM合并CVD的有效性和安全性较好;经济性结论在不同国家存在差异,在我国当前医疗政策及药品价格背景下达格列净具有经济学优势。
文摘目的探讨中西医结合治疗糖尿病心血管自主神经病变(DCAN)的临床疗效。方法选取2021年1月至2023年5月于石家庄市第二医院就诊的80例DCAN患者作为研究对象,采用随机数字表法分为对照组(40例)和观察组(40例),对照组采取常规西医治疗,观察组在对照组基础上采用中医综合治疗(益气养阴活血汤+针灸),1个疗程为14 d,2个疗程宜间隔7 d,两组共治疗3个疗程。比较两组临床疗效;比较两组空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR);比较两组窦性RR间期标准差(SDNN)、全程NN节段的窦性RR间期标准差(SDANN)、全程相邻RR之差的均方根(RMSSD)、相邻RR间期差值>50 ms的个数占总窦性心搏个数的百分比(PNN50);比较两组不良反应发生率。结果观察组临床总有效率(90.00%)明显高于对照组(70.00%),差异有统计学意义(P<0.05)。两组治疗后FBG、2 h PBG、HbA1c、HOMA-IR均明显低于治疗前,且观察组均明显低于对照组,差异均有统计学意义(P<0.05)。两组治疗后SDNN、SDANN、RMSSD、PNN50均明显高于治疗前,且观察组均明显高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论中西医结合治疗DCAN临床疗效明显,能够有效改善血糖水平、心率变异性,且不增加不良反应,具有较高的临床参考价值。
文摘目的探究达格列净联合常规治疗对2型糖尿病伴心力衰竭患者的心血管保护作用及对血清炎症因子和可溶性生长刺激表达基因2(sST2)水平的影响。方法前瞻性选取2020年9月至2022年8月江苏省昆山市第一人民医院收治的86例2型糖尿病伴心力衰竭患者为研究对象,按随机数字表法分为对照组和观察组,各43例。对照组予以常规治疗降糖及抗心力衰竭治疗,观察组在对照组基础上增加达格列净治疗。比较两组治疗前、治疗6个月后的血糖[糖化血红蛋白(HbA1c)、空腹血糖、餐后2 h血糖(2 h PG)]、血脂[总胆固醇、甘油三酯、低密度脂蛋白胆固醇(LDL-C)]、心功能[左心室射血分数(LVEF)、血浆N端脑钠肽前体(NT-proBNP)、6 min步行试验(6MWT)]、血清指标[白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、sST2]水平及心血管事件及不良反应发生率。结果治疗6个月后,观察组的HbA1c、空腹血糖、2 h PG、总胆固醇、甘油三酯、LDL-C水平分别为(6.65±0.73)%、(6.25±1.54)mmol/L、(7.88±1.35)mmol/L、(3.87±0.85)mmol/L、(1.52±0.46)mmol/L、(2.41±0.63)mmol/L,均明显低于对照组[(7.07±0.85)%、(7.16±1.49)mmol/L、(8.82±1.48)mmol/L、(4.24±0.82)mmol/L、(1.73±0.51)mmol/L、(2.69±0.61)mmol/L],差异均有统计学意义(P<0.05)。治疗6个月后,观察组的LVEF、6MWT水平分别为(52.28±3.43)%、(424.87±72.58)m,均明显高于对照组[(50.79±3.25)%、(367.52±74.43)m],血浆NT-proBNP水平为(1778.65±224.37)pg/mL,低于对照组[(2943.41±256.22)pg/mL],差异均有统计学意义(P<0.05)。治疗6个月后,观察组的血清IL-1β、TNF-α、sST2水平分别为(6.60±1.14)pg/mL、(22.15±4.30)ng/L、(0.42±0.13)g/L,均明显低于对照组[(7.19±1.39)pg/mL、(29.68±5.24)ng/L、(0.50±0.16)g/L],差异均有统计学意义(P<0.05)。观察组心血管事件总发生率为9.30%,低于对照组(25.58%),差异有统计学意义(P<0.05)。两组均无严重不良反应发生。结论在使用常规降糖、抗心力衰竭治疗2型糖尿病伴心力衰竭患者基础上增加达格列净可有效降低其血糖、血脂及血清IL-1β、TNF-α、sST2水平,减少心血管事件的发生,具有一定心血管保护作用。
